Next Article in Journal
The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information
Previous Article in Journal
Attitudes towards Social Networking and Sharing Behaviors among Consumers of Direct-to-Consumer Personal Genomics
Previous Article in Special Issue
Structured Decision-Making: Using Personalized Medicine to Improve the Value of Cancer Care
J. Pers. Med. 2013, 3(4), 288-305; doi:10.3390/jpm3040288
Review

Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned

1,* , 2
, 3
, 3
 and 3
Received: 8 October 2013; in revised form: 18 October 2013 / Accepted: 18 October 2013 / Published: 25 October 2013
View Full-Text   |   Download PDF [388 KB, uploaded 25 October 2013]
Abstract: Ten years after completion of the Human Genome Project, progress towards making “personalized medicine” a reality has been slower than expected. The reason is twofold. Firstly, the science is more difficult than expected. Secondly, limited progress has been made in aligning economic incentives to invest in diagnostics. This paper develops nine case studies of “success” where diagnostic tests are bringing personalized medicine into clinical practice with health and economic impact for patients, healthcare systems, and manufacturers. We focus on the availability of evidence for clinical utility, which is important not only for clinicians but also for payers and budget holders. We find that demonstrating diagnostic clinical utility and the development of economic evidence is currently feasible (i) through drug-diagnostic co-development, and (ii) when the research is sponsored by payers and public bodies. It is less clear whether the diagnostic industry can routinely undertake the work necessary to provide evidence as to the clinical utility and economic value of its products. It would be good public policy to increase the economic incentives to produce evidence of clinical utility: otherwise, opportunities to generate value from personalized medicine—in terms of both cost savings and health gains—may be lost.
Keywords: diagnostics; companion-diagnostics; personalized medicine; clinical utility; economic value; decision-making diagnostics; companion-diagnostics; personalized medicine; clinical utility; economic value; decision-making
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Towse, A.; Ossa, D.; Veenstra, D.; Carlson, J.; Garrison, L. Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. J. Pers. Med. 2013, 3, 288-305.

AMA Style

Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned. Journal of Personalized Medicine. 2013; 3(4):288-305.

Chicago/Turabian Style

Towse, Adrian; Ossa, Diego; Veenstra, David; Carlson, Josh; Garrison, Louis. 2013. "Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned." J. Pers. Med. 3, no. 4: 288-305.


J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert